U.S. Medical Equipment Stock News

NI Holdings stock barely moved after earnings, with a 0.5% gain that suggests investors shrugged at the headline. That calm reaction contrasts with a quarterly profit line that almost vanished. Basic earnings per share for Q2 came in around flat at just over US$0.01, following a far stronger start to 2026. The key issue for NI Holdings now appears to be sentiment. The stock carries a trailing P/E of 40.8x while net profit margin sits under 3%. That mix raises a clear question for investors...

Syndax Pharmaceuticals has delivered a 63.5% gain over the past year, yet the broader valuation checks and current market multiples suggest the stock is not an obvious bargain at today’s price of US$20.40. The 63.5% one year return points to strong recent optimism already reflected in Syndax Pharmaceuticals' share price. Progress on its oncology pipeline and upcoming clinical data can support expectations for future revenue, while the execution and clinical risks around those same programs...

Amkor Technology (AMKR) has drawn fresh attention after reporting second quarter 2026 results with higher sales and net income than a year earlier, alongside third quarter guidance that points to further earnings strength. See our latest analysis for Amkor Technology. Amkor Technology's recent earnings and guidance arrived alongside a mixed share price pattern, with a 10.83% 7 day share price gain following a period where the 30 day and 90 day share price returns declined 21.57% and 27.93%...

In early August 2026, Fi Inc. and Verizon Communications integrated the Fi Mini pet tracker into the Verizon Family app, creating a unified safety dashboard that extends real-time location, activity monitoring, and safe‑zone alerts from family members to pets within a single platform for Verizon postpaid customers. This collaboration highlights Verizon’s effort to deepen its role in the connected home by folding pets into the same digital safety ecosystem as people, potentially increasing...

Earlier this week, Globant launched Glob.AI, an AI-native tech services model delivering enterprise-grade AI Pods with output-based pricing, governance controls, and partnerships spanning Anthropic, AWS, OpenAI, Adobe, Azure, Google Cloud Platform, SAP and Salesforce. The move shifts Globant further toward an AI-centered, outcome-based services platform, with AI Pods already showing material efficiency gains for large clients like FIFA, LALIGA, YPF, PharmaMar and a major commercial...

In early August 2026, Horace Mann Educators Corporation reported second-quarter revenue of US$443.5 million and net income of US$41.6 million, both higher than a year earlier, alongside record core earnings and an increased 2026 core earnings guidance range of US$4.60–US$4.90 per share. The company also highlighted sharply improved property-and-casualty profitability, with a stronger combined ratio, and announced acquisitions expected to add meaningfully to annual run-rate earnings per share...

Gig economy platforms are back in the spotlight as regulators question how flexible work should really function, and that tension is putting stocks linked to this model under fresh scrutiny. For investors, that mix of legal risk and business growth can create sharp shifts in sentiment that reward those who are prepared. This article unpacks three stocks exposed to the latest gig work headlines and explains how the current scrutiny might shape their risk and return profiles. The stocks covered...

Wendy’s stock bounced about 4% to US$7.69 into the first full trading day after earnings, even as the headline story is pressure, not comfort. Same restaurant sales declined 6.3% in the quarter and global systemwide sales fell 6.5%. That mix of a cheaper stock on an earnings pop and falling traffic is what matters for you as an investor. In the near term, the focus is on weaker guest counts and a thinner 5.7% trailing net margin. Over the longer term, the key question is whether the new...

Recent performance snapshot for Berkshire Hathaway stock Berkshire Hathaway (BRK.B) has drawn fresh attention after its share price closed at US$521.80 on 6 August 2026. The stock shows mixed short term moves, with a small daily decline and gains over the past week. Over the past month and past 3 months, Berkshire Hathaway has delivered positive total returns, along with gains over the year to date and past year. Longer term figures over the past 3 years and 5 years also show positive total...

In early August 2026, Atlassian reported fourth-quarter and full-year results showing revenue rising to US$1,766.47 million for the quarter and US$6.57 billion for the year, alongside a shift from a quarterly loss to a quarterly profit and new guidance calling for approximately 13% total revenue growth in fiscal 2027. The company also highlighted accelerating cloud and AI adoption, announced CEO Mike Cannon-Brookes’ plan to purchase up to US$250 million of Atlassian shares, and appointed Ken...

The fight over Fifa’s abandoned $4.2b World Cup stake has drawn attention to something bigger. Tech investors are hunting for assets that feel resilient as AI reshapes movies, games and streaming, and global sports sit right in that crosshairs. For anyone focused on where long term attention and money may concentrate, this matters. This article breaks down three stocks tied to that story and explains how the same news affects each of them. Manchester United (MANU) Manchester United runs one...

Middle East partnership puts Gap in focus Gap (GAP) is drawing fresh attention after agreeing to partner with Dubai based Chalhoub Group to introduce Gap, Banana Republic, and Athleta across the UAE, Saudi Arabia, and Kuwait from 2026. See our latest analysis for Gap. Set against a year to date share price return that is down 18.74% and a 1 year total shareholder return of 6.56%, Gap’s new Middle East partnership lands while short term share price momentum has softened and the longer term...

Ziff Davis (ZD) stock is in focus after the company reported second quarter 2026 results, with sales of US$286.74 million, a sharp swing in net income, and a loss from continuing operations. See our latest analysis for Ziff Davis. The earnings update and the sale of the connectivity business to Accenture for about US$1.2b have come alongside strong recent momentum in Ziff Davis, with a 90 day share price return of 28.58% and a 1 year total shareholder return of 46.86%, although the 5 year...

Why Option Care Health stock is in focus after its latest update Option Care Health (OPCH) is drawing fresh attention after reporting second quarter 2026 results, with revenue, EBITDA, and EPS ahead of expectations, while keeping guidance unchanged and continuing investments in digital tools and infusion clinic expansion. See our latest analysis for Option Care Health. Against this backdrop, Option Care Health's recent earnings and buyback activity appear to be supporting improving sentiment...

In early August 2026, MetLife, Inc. reported second-quarter revenue of US$19,154 million and net income of US$736 million, alongside higher diluted earnings per share from continuing operations versus a year earlier, and stronger results for the first half of 2026. On the same day, MetLife’s board authorized a new US$3.00 billion share repurchase program after completing US$2.63 billion of buybacks since April 2025, underscoring the insurer’s current emphasis on returning capital to...

Gray Media stock exploded 25% higher to US$5.37 after the Q2 report, a sharp move for a regional television and media operator that has been wrestling with losses. The headline number was Q2 revenue of US$839 million, helped by US$83 million of political advertising that came in ahead of expectations. Basic earnings per share remained in loss territory, although the loss narrowed compared with recent quarters. For short term traders, the pop is the story. For longer term holders, the bigger...

Zai Lab stock has rebounded sharply over the short term, yet its longer term share price record and current valuation checks point to a more cautious picture for investors trying to judge what the recent move really means. Over the past 5 years, Zai Lab has fallen about 84.5%, which leaves long term holders with a material drawdown even after the recent bounce. Regulatory progress such as Orphan Drug Designation for its DLL3-targeting therapy Zocilurtatug Pelitecan can support expectations...

Earlier this week, Cheniere Energy reported past second-quarter 2026 results showing revenue of US$5,732 million and net income of US$3,068 million, raised its full-year 2026 net income guidance to US$1.60–US$2.00 billion, tightened production guidance to 53–54 million tonnes, completed a multi-year US$9.27 billion buyback program, and reaffirmed a US$0.555 quarterly dividend. The combination of higher earnings and production guidance, large-scale share repurchases, and ongoing LNG capacity...

Allient Inc. recently reported second-quarter 2026 results showing sales of US$153.77 million and net income of US$10.39 million, alongside a Board-approved quarterly cash dividend of US$0.04 per share payable on September 2, 2026, to shareholders of record on August 19, 2026. With higher earnings per share from continuing operations and a continued cash dividend across roughly 17.0 million shares, Allient is signaling both improved profitability and a commitment to returning cash to...

Lineage earnings snapshot after second quarter results Lineage (LINE) released second quarter 2026 earnings on 5 August, with sales of US$1.361b and a net loss of US$29 million. That compares with sales of US$1.350b and a US$6 million loss a year earlier. For the first half of 2026, Lineage reported sales of US$2.658b and a net loss of US$75 million. Basic and diluted loss per share from continuing operations was US$0.31, compared with US$0.02 for the same period in 2025. See our latest...

Celldex Therapeutics stock has more than doubled over the past year, yet the latest valuation checks and market multiples suggest the shares lean expensive rather than clearly cheap. The 101.9% return over the past year highlights how strongly sentiment has shifted toward Celldex Therapeutics, which raises the bar for what the current price can justify. Progress in Celldex Therapeutics' barzolvolimab and CDX-622 programs can support expectations for future growth. However, trial setbacks or...

In recent days, Sigma Lithium Corporation, a Brazil-focused lithium developer based in Toronto, saw investor attention increase after an analyst upgraded the stock to a Buy rating, reflecting improving sentiment toward its role in the electric vehicle battery supply chain. This shift in analyst stance underscores how external research views can influence confidence in Sigma Lithium’s position within the global lithium-ion ecosystem. Next, we’ll examine how the recent analyst upgrade may...

FuboTV stock has seen a very steep long term decline, yet its current valuation checks still suggest the shares may be pricing in more pessimism than the fundamentals imply. FuboTV shareholders have seen the stock fall about 97.3% over the past 5 years, which means current buyers are looking at a very different risk and reward profile to those who bought earlier in its story. Future revenue growth and progress toward more consistent cash generation can support the current valuation, while...

Annaly Capital Management stock triggered review Annaly Capital Management (NLY) is back on investor radar after recent share price moves, with the stock closing at US$23.04 on 5 August 2026 and showing mixed short term and longer term returns. See our latest analysis for Annaly Capital Management. The recent 1 day share price return of 1.68% adds to a steady but modest trend over the past quarter, while total shareholder return of 27.54% over one year and 73.59% over three years highlights...